B. J. Mavunkel et al. / Bioorg. Med. Chem. Lett. 13 (2003) 3087–3090
3089
(
activity in comparison to 6.
IC =1.65 mM) showed almost no improvement in
5. Adams, J. L.; Boehm, J. C.; Kassis, S.; Gorycki, P. D.;
Webb, E. F.; Hall, R.; Sorenson, M.; Lee, J. C.; Ayrton, A.;
Griswold, D. E.; Gallagher, T. F. Bioorg. Med. Chem. Lett.
5
0
1
6
998, 8, 3111.
. de Laszlo, S. E.; Visco, D.; Agarwal, L.; Chang, L.; Chin,
J.; Croft, G.; Forsyth, A.; Fletcher, D.; Frantz, B.; Hacker, C.;
Hanlon, W.; Harper, C.; Kostura, M.; Li, B.; Luell, S.; Mac-
Coss, M.; Mantlo, N.; O’Neill, E. A.; Orevillo, C.; Pang, M.;
Parsons, J.; Rolando, A.; Sahly, Y.; Sidler, K.; O’Keefe, S. J.
Bioorg. Med. Chem. Lett. 1998, 8, 2698.
7. Revesz, L.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram,
H.; Hiestand, P.; Manning, U.; Zimmerlin, A. G. Bioorg. Med.
Chem. Lett. 2000, 10, 1261.
Molecular modeling studies (Fig. 3),27 of (+)-9 and (À)-
1
0 supports the observation that the highly con-
formationally restricted analogue (+)-9 should be more
potent than (À)-10. Thus, in (+)-9 the substitution
pattern helps restrict the analogue and only populate
the proposed active binding conformation, whereas this
is not the case in (À)-10. Though it is obvious that the
increase in potency of (Æ)-8 is due to the entropic effect
of a conformationally restricted analogue, at this time it
is not possible to rule out any secondary contributions
due to a hydrophobic interactions of the substituents on
the piperazine moiety and/or the indole ring and the
binding pocket of p38a.
8. Fijen, J. W.; Zijlstra, J. G.; De Boer, P.; Spanjersberg, R.;
Cohen Tervaert, J. W.; Van Der Werf, T. S.; Ligtenberg, J. J.;
Tulleken, J. E. Clin. Exp. Immunol. 2001, 124, 16.
9
. Wadsworth, S. A.; Cavender, D. E.; Beers, S. A.; Lalan, P.;
Schafer, P. H.; Malloy, E. A.; Wu, W.; Fahmy, B.; Olini,
G. C.; Davis, J. E.; Pellegrino-Gensey, J. L.; Wachter, M. P.;
Siekierka, J. J. J. Pharmacol. Exp. Ther. 1999, 291, 680.
1
0. Collis, A. J.; Foster, M. L.; Halley, F.; Maslen, C.;
McLay, I. M.; Page, K. M.; Redford, E. J.; Souness, J. E.;
Wilsher, N. E. Bioorg. Med. Chem. Lett. 2001, 11, 693.
11. McLay, L. M.; Halley, F.; Souness, J. E.; McKenna, J.;
Benning, V.; Birrell, M.; Burton, B.; Belvisi, M.; Collis, A.;
Constan, A.; Foster, M.; Hele, D.; Jayyosi, Z.; Kelley, M.;
Maslen, C.; Miller, G.; Ouldelhkim, M. C.; Page, K.; Phipps,
S.; Pollock, K.; Porter, B.; Ratcliffe, A. J.; Redford, E. J.;
Webber, S.; Slater, B.; Thybaud, V.; Wilsher, N. Bioorg. Med.
Chem. 2001, 9, 537.
1
2. Ge, B.; Gram, H.; Di Padova, F.; Huang, B.; New, L.;
Ulevitch, R. J.; Luo, Y.; Han, J. Science 2002, 295, 1291.
3. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher,
1
T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.;
Heys, J. R.; Landvatter, S. W. Nature 1994, 372, 739.
1
4. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.;
Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-
Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.;
Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.;
Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell,
P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Bioorg. Med.
Chem. 1997, 5, 49.
In conclusion, following the discovery from high
throughput screening, initial SAR studies were carried
out on a novel series of p38a MAP kinase inhibitors.
The results of these studies led to a preliminary identifi-
cation of the important structural features of these
compounds. The potency of these compounds were
dramatically enhanced by the rational design of con-
formationally restricted analogues and led to the iden-
tification of a potent inhibitor of p38a MAP kinase.
1
5. Purves, T.; Middlemas, A.; Agthong, S.; Jude, E. B.;
Boulton, A. J.; Fernyhough, P.; Tomlinson, D. R. FASEB J.
2001, 15, 2508.
16. Igarashi, M.; Wakasaki, H.; Takahara, N.; Ishii, H.;
Jiang, Z. Y.; Yamauchi, T.; Kuboki, K.; Meier, M.; Rhodes,
C. J.; King, G. L. J. Clin. Invest. 1999, 103, 185.
17. Manson, M. M.; Holloway, K. A.; Howells, L. M.; Hud-
son, E. A.; Plummer, S. M.; Squires, M. S.; Prigent, S. A.
Biochem. Soc. Trans. 2000, 28, 7.
1
8. Ding, Q.; Wang, Q.; Evers, B. M. Biochem. Biophys. Soc.,
Trans. 2001, 284, 282.
9. Synthesis of 1: 0.382 g of benzylpiperazine was dissolved
1
References and Notes
in 10 mL DMF, to this was added 0.322 g of indole-5-car-
boxylic acid and 0.382 g of EDAC. To the reaction mixture
was added 10 mg mL of dimethylaminopyridine. The reaction
mixture was stirred at room temperature for 2 h. The contents
of the reaction mixture were poured into 50 mL water and
extracted with 3Â30 mL chloroform. The choloroform layer
was washed with water and 2Â20 mL aq sodium carbonate
(5%) solution, and brine. After drying over anhydrous sodium
sulfate and filtration, solvent was removed to give a crude
residue that was re-dissolved in the minimal amount of
chloroform and chromatographed on silica gel, using chloro-
form/methanol 99/1. The fractions corresponding to the
desired product were pooled and concentrated to give a white
solid. 257 mg. This material was re-dissolved in the minimal
amount of dichloromethane to this was added 2.5 mL 2 N HCl
1
2
2
. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. Science 1994,
65, 808.
. Jiang, Y.; Chen, C.; Li, Z.; Guo, W.; Gegner, J. A.; Lin, S.;
Han, J. J. Biol. Chem. 1996, 271, 17920.
. Li, Z.; Jiang, Y.; Ulevitch, R. J.; Han, J. Biochem. Biophys.
Res. Commun. 1996, 228, 334.
. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.;
Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-
Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.;
Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.;
Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell,
P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Bioorg. Med.
Chem. 1997, 5, 49.
3
4